Clinical outcomes in immunocompromised adults with COVID-19, based on anti-spike IgG serostatus and monoclonal antibody therapy: a retrospective cohort study in the Omicron period

Therapeutic Advances in Infectious Disease, Год журнала: 2025, Номер 12

Опубликована: Янв. 1, 2025

Background: Immunocompromised adults may experience severe COVID-19 outcomes, necessitating a multifaceted treatment approach. Studies from the Delta period showed benefit monoclonal antibody (mAb) therapy that was most pronounced among anti-spike IgG seronegative individuals. With widespread vaccination and shifting SARS-CoV-2 variants in Omicron period, clinical predictors of seronegativity, impacts on remain incompletely characterized. Objectives: We describe outcomes cohort immunocompromised with stratified by serostatus receipt mAb during to evaluate impact. Design: This retrospective study mild-moderate presenting between December 2021 October 2022. Methods: Charts were reviewed assess serostatus, therapy, 28-day including conventional oxygen use, high-flow mechanical ventilation, death. Results: A total 276 individuals included, whom 252 (91%) partially or fully vaccinated, 190 (69%) seropositive, 225 (82%) received therapy. majority solid organ transplant recipients (169, 61%), seronegatively significantly associated mycophenolate-based immunosuppression comorbid chronic kidney disease. Conventional use seropositive patients receiving mAb, not 2/154 (1%), 5/71 (7%), 6/36 (17%), 4/15 (27%), respectively. Across cohort, death occurred 6 (2%), 4 (3%), 3 (1%) individuals, Conclusion: Clinical predominantly mild–moderate appeared vary Observed trends would prospective studies future iterations therapeutics inform decisions for adults.

Язык: Английский

---

Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics

Vaccine, Год журнала: 2025, Номер 54, С. 126960 - 126960

Опубликована: Март 7, 2025

Язык: Английский

---

Replication Features of SARS-CoV-2 and Advantages of Targeting S Protein with Aptamers to Block Viral Entry

ACS Omega, Год журнала: 2025, Номер unknown

Опубликована: Апрель 21, 2025

Язык: Английский

---

Using Passive Antibody Therapies in the Next Pandemic

Current topics in microbiology and immunology, Год журнала: 2024, Номер unknown

Опубликована: Янв. 1, 2024

Язык: Английский

---